Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-0087PMID 16857819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome

  2006cited by this paper
• Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  2005cited by this paper
• Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Prognostic significance of epidermal growth factor receptor in surgically treated squamous cell lung cancer patients.

  2004cited by this paper
• Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.

  2004cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.

  2003cited by this paper
• Prognostic factors in non-small cell lung cancer.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

  2003cited by this paper
• The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

  2002cited by this paper

• Meta-learning-based Inductive logistic matrix completion for prediction of kinase inhibitors

  2024cites this paper
• Establishment of primary reference measurement procedures and reference materials for EGFR variant detection in non-small cell lung cancer.

  2021cites this paper
• Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients

  2018cites this paper
• Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile

  2017cites this paper
• Design and Analysis of Clinical Trials for Predictive Medicine

  2015cites this paper
• Personalized treatment options in Non-small Cell Lung Cancer

  2014cites this paper
• MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer.

  2014cites this paper
• Chapter 59 – Lung Cancer

  2013cites this paper
• Molecular pathology of lung cancer

  2013cites this paper
• Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer

  2012cites this paper
• High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

  2012cites this paper
• Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 2.

  2012cites this paper
• Ancillary Testing in Lung Cancer Diagnosis

  2012cites this paper
• Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer.

  2012cites this paper
• Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma

  2011cites this paper
• The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.

  2011cites this paper
• The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.

  2011cites this paper
• Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer.

  2011cites this paper
• Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

  2010cites this paper
• Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens.

  2010cites this paper
• Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer

  2010cites this paper
• Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR

  2010cites this paper
• Role of Pathology and Immunohistochemistry in the New Era Of Molecular Therapy

  2010cites this paper
• Amplification of epidermal growth factor receptor gene in renal cell carcinoma.

  2010cites this paper
• Implementação da técnica Silver In Situ Hibridization para avaliação do status do gene EGFR em doentes com CPNPC

  2010cites this paper
• Targeting EGFR in HPV-Associated Cancer

  2010cites this paper
• Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

  2010cites this paper
• Genomics in the Diagnosis and Management of Lung Cancer

  2010cites this paper
• Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer

  2009cites this paper
• Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation.

  2009cites this paper
• CHAPTER 71 – Genomics of Lung Cancer

  2009cites this paper
• Targeted therapies in the treatment of advanced/metastatic NSCLC.

  2009cites this paper
• [Advances of Targeted therapies in Non-small Cell Lung Cancer.].

  2009cites this paper
• Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma

  2009cites this paper
• Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

  2008cites this paper
• Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites

  2008cites this paper
• [The relationship between genetic polymorphism of GSTM1 and the outcome of chemotherapy in Chinese patients with primary lung cancer.].

  2008cites this paper
• Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities

  2008cites this paper
• VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.

  2008cites this paper
• Newer Cytotoxic Agents: Attacking Cancer Broadly

  2008cites this paper
• EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

  2008cites this paper
• Neue Wege zur Früherkennung, Prognoseabschätzung und Therapie maligner Tumoren des Gastrointestinaltraktes

  2008cites this paper
• Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer

  2008cites this paper
• Novel CHD 5 , a tumor suppressor gene in neuroblastomas

  2008cites this paper
• Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology.

  2008cites this paper
• The ERBB3 receptor in cancer and cancer gene therapy

  2008cites this paper
• Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers

  2007cites this paper
• Key signaling pathways and targets in lung cancer therapy.

  2007cites this paper
• Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

  2007cites this paper
• Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR).

  2007cites this paper
• Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

  2007influential citation
• Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab

  2007cites this paper
• Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

  2007cites this paper
• Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

  2007cites this paper
• The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor.

  2007cites this paper
• Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer

  2007cites this paper
• Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non–Small Cell Lung Cancer

  2007influential citation
• Recommendations for Improved Standardization of Immunohistochemistry

  2007cites this paper
• Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

  2007cites this paper
• INTEGRATING RADIOTHERAPY WITH EGFR ANTAGONISTS AND OTHER MOLECULAR THERAPEUTICS FOR THE TREATMENT OF HEAD AND NECK CANCER

  2007cites this paper
• Combination of radiotherapy with EGFR antagonists for head and neck carcinoma

  2007cites this paper
• The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor.

  2007cites this paper
• Chinese a Nti鄄 Cancer a Ssociation

  year unknowncites this paper